找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Complement Therapeutics; John D. Lambris,V. Michael Holers,Daniel Ricklin Book 2013 Springer Science+Business Media New York 2013 infectio

[复制链接]
查看: 23130|回复: 61
发表于 2025-3-21 19:38:37 | 显示全部楼层 |阅读模式
书目名称Complement Therapeutics
编辑John D. Lambris,V. Michael Holers,Daniel Ricklin
视频videohttp://file.papertrans.cn/232/231284/231284.mp4
概述Proceedings from the 5th International Complement Theraputics Conference.Part of the Aegean Conferences series.Incorporates cutting-edge research and showcases methods developed and perfected in the l
丛书名称Advances in Experimental Medicine and Biology
图书封面Titlebook: Complement Therapeutics;  John D. Lambris,V. Michael Holers,Daniel Ricklin Book 2013 Springer Science+Business Media New York 2013 infectio
描述.This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. In addition, complement is often involved in adverse immune reactions to biomaterials, cell and organ transplants or drug delivery systems. Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials.. .The chapters in this book cover a wide range of topics related to th
出版日期Book 2013
关键词infectious diseases
版次1
doihttps://doi.org/10.1007/978-1-4614-4118-2
isbn_softcover978-1-4899-7823-3
isbn_ebook978-1-4614-4118-2Series ISSN 0065-2598 Series E-ISSN 2214-8019
issn_series 0065-2598
copyrightSpringer Science+Business Media New York 2013
The information of publication is updating

书目名称Complement Therapeutics影响因子(影响力)




书目名称Complement Therapeutics影响因子(影响力)学科排名




书目名称Complement Therapeutics网络公开度




书目名称Complement Therapeutics网络公开度学科排名




书目名称Complement Therapeutics被引频次




书目名称Complement Therapeutics被引频次学科排名




书目名称Complement Therapeutics年度引用




书目名称Complement Therapeutics年度引用学科排名




书目名称Complement Therapeutics读者反馈




书目名称Complement Therapeutics读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:26:38 | 显示全部楼层
发表于 2025-3-22 01:15:57 | 显示全部楼层
发表于 2025-3-22 06:59:32 | 显示全部楼层
发表于 2025-3-22 09:12:14 | 显示全部楼层
https://doi.org/10.1057/9780230349414ex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The bind
发表于 2025-3-22 15:22:06 | 显示全部楼层
Captivating Quanzhou Specialties,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1
发表于 2025-3-22 18:14:46 | 显示全部楼层
发表于 2025-3-22 23:18:22 | 显示全部楼层
发表于 2025-3-23 02:18:54 | 显示全部楼层
Janine O. Ilagan,Melissa S. Juricand (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove
发表于 2025-3-23 05:50:40 | 显示全部楼层
Klaus Böhmer,Günter Meinardus,Walter SchemppPNH was an appropriate medical condition to develop and to investigate therapeutical complement inhibitors. Indeed, the first complement inhibitor eculizumab, a humanized anti-C5 monoclonal antibody, has been proven safe and effective for the treatment of PNH patients. Chronic treatment with eculizu
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-24 21:42
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表